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Abstract
Background: At present pathogenic mechanisms of cancer cachexia are poorly understood.
Previous evidence in animal models implicates the melanocortin-4 receptor gene (MC4R) in the
development of cancer cachexia. In humans, MC4R mutations that lead to an impaired receptor
function are associated with obesity; in contrast, the most frequent polymorphism (Val103Ile,
rs2229616; heterozygote frequency approximately 2%) was shown to be negatively associated with
obesity. We tested if cancer patients that are homo-/heterozygous for the Val103Ile polymorphism
are more likely to develop cachexia and/or a loss of appetite than non-carriers of the 103Ile-allele.
Methods: BMI (body mass index in kg/m2) of 509 patients (295 males) with malignant neoplasms
was determined; additionally patients were asked about premorbid/pretherapeutical changes of
appetite and weight loss. Cachexia was defined as a weight loss of at least 5% prior to initiation of
therapy; to fulfil this criterion this weight loss had to occur independently of other plausible
reasons; in single cases weight loss was the initial reason for seeing a physician. The average age in
years (± SD) was 59.0 ± 14.5 (males: 58.8 ± 14.0, females 59.2 ± 14.0). Blood samples were taken
for genotyping of the Val103Ile by PCR- RFLP.
Results: Most of the patients suffered from lymphoma, leukaemia and gastrointestinal tumours.
107 of the patients (21%) fulfilled our criteria for cancer cachexia. We did not detect association
between the Val103Ile polymorphism and cancer cachexia. However, if we exploratively excluded
the patients with early leucaemic stages, we detected a trend towards the opposite effect (p <
0.05); heterozygotes for the 103Ile-allele developed cancer cachexia less frequently in comparison
to the rest of the study group. Changes of appetite were not associated with the 103Ile-allele
carrier status (p > 0.39).
Conclusion: Heterozygotes for the 103Ile-allele are not more prone to develop cancer cachexia
than patients without this allele; possibly, Ile103 carriers might be more resistant to cancer cachexia
in patients with solid tumors. Further studies of the melanocortinergic system in cachexia of
patients with solid tumors are warranted.
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Background
The cachexia syndrome represents a complex metabolic
state accompanied by muscle wasting and a loss of body
fat, hence quality of life is deteriorated and the prognosis
of the patients who suffer from it is reduced [1,2]. Reports
mostly vary in the amount of weight loss (5–10%) and the
time span (6–12 months) in which the weight loss occurs
[3-7]. Up to one-half of untreated cancer patients is
expected to lose weight while about one third is expected
to lose more than 5%; about 20% of cancer deaths may be
due to cachexia [3]. Anorexia, defined as the loss of appe-
tite and early satiety, is present in up to one-half of newly
diagnosed cancer patients [8]. In addition, a number of
non-specific factors associated with cancer (e.g. changes in
taste and smell, vomiting, pain) may contribute to limited
food intake. However, loss of appetite is not obligatory for
the development of cachexia [4].
Although a formal classification for cancer cachexia does
not exist, it can be presumed that a variable interaction of
tumour products, neuroendocrine changes, and host
inflammatory molecules leads to this observable wasting
[5]. At present the mechanisms in the pathogenesis of can-
cer cachexia are still poorly understood. Here, the poten-
tial role of the melanocortin-4 receptor gene (MC4R) was
investigated.
The MC4R is part of the leptinergic-melanocortinergic
pathway that controls energy homeostasis. Stimulation of
MC4R leads to higher energy expenditure, loss of appetite
and weight loss [9]. A series of experiments demonstrated
that cancer cachexia is ameliorated by central MC4R
blockade in MC4R knock out mice or by peripheral
administration of an antagonist (e.g. agouti-related pro-
tein – AGRP) in rats, mice and sheep [9-13]. Orally bioa-
vailable potent antagonists of the human MC4R (e.g.
synthesized compounds of Pyrrolidinones) demonstrated
in vivo efficacy in protecting against cachectic symptoms in
animal models of tumour-induced wasting and may be a
suitable approach for the treatment of cachexia [14,15].
In humans, mutations that reduce the function of the
MC4R result in severe obesity [16-18]. The Val103Ile pol-
ymorphism is the most common MC4R  variant, with
allele frequencies > 1% in almost all studied populations
[17,19-22]. This polymorphism was repeatedly shown to
be negatively associated with above average weight and
obesity in humans [21-23]. Recently, the initial finding
(Geller et al., 2004) was replicated in an independent
sample [24] comprising 5.603 individuals. Young et al.
(2007) confirmed these findings in a meta-analysis com-
prising 29,563 individuals: individuals harbouring the Ile
allele had an 18% lower risk of obesity compared with
non-carriers [23]. The Ile103 variant is assumed to entail
a higher receptor activity [24,25].
Our primary objective was to evaluate the role of the
MC4R Val103Ile polymorphism in the development of
cachexia in patients with cancer. We hypothesized that
cancer patients with the 103Ile-allele of the MC4R  are
more likely to develop cancer cachexia than patients with-
out the respective allele. Furthermore we analyzed if loss
of appetite independent of therapy and thus disease-
related, is associated with the 103Ile-allele.
Methods
Subjects
509 consecutive patients from the outpatient unit of the
Department of Hematology, Oncology and Immunology
of the Philipps-University of Marburg were recruited from
October 2003 until November 2004. Written informed
consent was given by all participants. This study was
approved by the ethics committee of the Philipps-Univer-
sity of Marburg.
Questionnaire
Currently, there is no valid questionnaire to evaluate the
status of cachexia in cancer patients. Thus, a new semi-
structured interview was developed. Attention was paid to
the weight-changes that had occurred prior to initiation of
the cancer therapy. As a marker for cachexia we referred to
pretherapeutical weight loss if it occurred a) 1–12 months
prior to initiation of therapy and b) was not due to
mechanical obstruction of the oro-gastrointestinal tract,
c) could not readily be explained by a psychiatric disorder
(such as depression) or d) an intentional diet. Besides
data like date of birth, sex, type of cancer, stage of disease
and therapy the interview included questions about
weight, weight changes and appetite. Current height and
weight were measured. Often self-reports are the only
source of information about body weight in the past. Sev-
eral studies have examined factors affecting the validity of
self- reported past body weight [26-28]. The recalls partly
were influenced by age, sex, the passage of time, the accu-
racy of current weight reports, weight gain and loss, and
weight variability [26,28]. Nevertheless, past body
weights were recalled with good accuracy in all of these
studies.
Definition of cachexia in cancer patients
As definitions of cancer cachexia vary and as no generally
accepted standard exists [e.g. [3-7]], the patients were cat-
egorized in five different groups according to cachexia
severity type. Type 1–3 indicate cachexia, whereas type 4
and 5 indicate a non-cachectic situation:
Type 1: definitely cachectic: weight loss of at least 10% of
pretherapeutical weight that cannot be explained by other
plausible reasons or which was the initial reason for see-
ing a physician. Weight loss as a consequence of therapy
or oro-gastrointestinal obstruction (stenosis, etc.) couldBMC Cancer 2008, 8:85 http://www.biomedcentral.com/1471-2407/8/85
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definitely be ruled out. 44 of the 509 patients (8.6%) were
included in this type.
Type 2: cachexia very probable: weight loss of at least 10%
of pretherapeutical weight that cannot be explained by
other plausible reasons or which was the initial reason for
seeing a physician. In contrast to type 1 we were not able
to completely exclude that some weight loss was due to
therapy (chemotherapy or radiation) or tumour related
mechanical reasons. 20 patients (3.9%) were included in
type 2.
Type 3: cachexia probable: weight loss of at least 5% but less
than 10% of pretherapeutical weight that can not be
explained by other plausible reasons or which was the ini-
tial reason for seeing a physician. In contrast to type 1 we
were not able to completely exclude that some weight loss
was due to therapy (chemotherapy or radiation) or
tumour related mechanical reasons. 43 patients (8.4)
were included in type 3.
Type 4: cachexia unlikely: a) weight loss of less than 5% or
b) weight loss in excess of 5% of pretherapeutical weight
that is most likely due to therapy (chemotherapy, radia-
tion, etc.) or a mechanical reason (weight loss occurred
after initiation of therapy; patient reported that obstruc-
tion led to reduction in food intake). 221 patients
(43.4%) were included in type 4.
Type 5: cachexia ruled out: a) no weight loss or b) weight
gain. 181 patients (35.6%) were included in type 5.
Classification of the tumor progression
The different tumour types were divided into different
classifications and stages that are related to prognostic val-
ues and are commonly used to define therapy options
(Table 1). In detail: for patients with colorectal or other
gastrointestinal cancers, breast and lung cancer we have
used the Union international contre le cancer classifica-
tion system [29]. We have used the World Health Organi-
zation (WHO) classification for subtypes of lymphomas
[30], the stages were defined according to the Ann Arbor
classification system [31], except for chronic lymphatic
leukaemia (CLL) which were classified according to the
classification of Binet [32]; and multiple myeloma which
were classified according to Durie and Salmon [33]. We
divided patients with all different above mentioned
tumour types (except for CLL and multiple myeloma) into
two groups: stage I/II (limited/intermediate diseases) and
stage III/IV (advanced diseases). All other analyzed
tumour types (prostate cancer, Primitive Neuroectoder-
mal Tumour (PNET), Carcinoma of unknown primary
(CUP) and other (rare) tumour types) were each to rare to
analyze them according to their stages.
Molecular genetic analysis
Blood samples were taken from all patients. DNA extrac-
tion and genotyping of the Val103Ile polymorphism was
performed by specific PCR-RFLP as described previously
[34].
Statistical Analyses
To test for association of cachexia status (types 1–3 vs.
types 4,5) with the Val103Ile MC4R polymorphism, the
genotype frequencies in the respective groups were com-
pared by Fisher's exact test. As only one hypothesis is
tested α was set to 0.05 (two-sided). For exploratory pur-
poses, post-hoc and sub-group analyses were conducted.
The genotype distribution in the total sample was tested
for deviations from Hardy Weinberg equilibrium (p = 1,
exact test). Assuming a minor allele frequency of 0.05, a
frequency of 0.2 for the type 1–3 cachexia status, and α =
Table 1: Different diagnoses and stages within the study group and the proportion of patients with cancer cachexia (types 1–3; see 
Methods)
Type of cancer N 
patients
Of these 
cachectic
I/II1,2 or 
related stages
Of these 
cachectic
III/IV1,2 or 
related stages
Of these 
cachechtic
No data 
about stage
n 
female
Of these 
cachectic
n 
male
Of these 
cachectic
Lymphoma1 202 (40) 35 (17.3) 57+ 9 (15.8) 61+ 22 (36.1) 16+ 84 18 (21.4) 118 17 (14.4)
Colorectal2 84 (16) 23 (27.4) 9 3 (33.3) 71 19 (26.8) 43 3 7 (21.2) 51 16 (31.4)
Leukaemia3 58 (11) 7 (12.1) *** 2 2 4 (18.2) 36 3 (8.3)
Other2 
Gastrointestinal
39 (8) 15 (38.5) 4 1 (25) 21 8 (38.1) 14 8 3 (37.5) 31 12 (38.7)
Lung2 36 (7) 9 (25) 6 1 (16.7) 27 8 (29.6) 39 3 (33.3) 27 6 (22.2)
Breast2 32 (6) 4 (12.5) 17 2 (11.8) 9 2 (22.2) 63 2 4 (12.5) 0
Leukaemia-early 
stages3,4
20 (4) 5 (25) *** 1 3 2 (15.4) 7 3 (42.9)
Prostate*4   (1) 1 (25) *** 4 1 (25)
Others* 34 (7) 8 (23.5) *** 1 3 5 (38.5) 21 3 (14.3)
Total 509 107 (21) **** * 214 46 (21.5) 295 61 (20.7)
Numbers in parentheses denote the particular percentage.
1Lymphoma subgroups according to WHO (2001) and Ann Arbor classifications.
+The 24 patients with CLL (classification of Binet) and the 44 patients with multiple myeloma (classification of Durie and Salmon) were excluded.
2UICC classification was used for colorectal and other gastrointestinal tumors, breast and lung cancer.
3The different classifications for leucaemia and the leukaemia-early stages could not be used for these groups.
4Patients with myelodysplastic syndromes (MDS) or myeloproliferative syndromes (MPD).
*The classifications for these tumour types could not be used for subgrouping.BMC Cancer 2008, 8:85 http://www.biomedcentral.com/1471-2407/8/85
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0.05 (two-sided, Fisher's exact test), the total sample sizes
of 509 individuals was estimated to yield a power of ≈0.80
to detect an odds ratio of ≈3.0. Hence the study is well
powered to detect strong associations between carrier sta-
tus and cachexia status.
Results
The different malignant diseases that were diagnosed in
our study group and the percentages of cachexia are
shown in Table 1. Our results are consistent with previous
reports that weight loss is more common in patients with
lung and gastrointestinal cancer and less common in
patients with breast cancer [3,35]. Patients with malignant
neoplasms according to ICD 10, including 14 patients
with myelodysplastic syndromes (MDS) and six patients
with myeloproliferative syndromes (MPD: polycythemia
vera, essential thrombocythemia, osteomyelofibrosis)
were included; these preleukaemic stages can transform
into acute myeloic leukaemia. Most of the patients suf-
fered from lymphoma, leukaemia and gastrointestinal
tumours.
The average age in years (± SD) was 59.0 ± 14.5 (males:
58.8 ± 14.0, females 59.2 ± 14.0). Average BMI of all 509
patients one year before diagnosis of cancer was 26.0 ± 3.4
kg/m2, at the time of diagnosis (prior to initiation of ther-
apy) 25.5 ± 3.7 kg/m2 and at ascertainment 25.3 ± 3.9 kg/
m2. 107 patients (21%) developed cancer cachexia (types
1–3, see Methods).
MC4R Val103Ile polymorphism
Among the total of 509 patients 25 (4.9%; average age
57.1 ± 16.6 years; 17 males) were heterozygous for the
Val103Ile polymorphism. Of these 2 developed cancer
cachexia (these two had non-neoplastic early leukaemic
stages). Of the remaining 484 patients with the wild type
genotype, 105 (21.7%) developed cancer cachexia (Table
2). In contrast to our primary hypothesis, there was no
evidence for an association of the Ile103 allele with cancer
cachexia (Fisher's exact test, two sided, p-value = 0.13). An
exploratory post-hoc exclusion of the 20 patients with
early leukaemic stages (Table 3), that can strictly be
viewed as non-neoplasms even revealed a trend towards a
negative association between the 103Ile polymorphism
and cancer cachexia (Fisher's exact test, two sided, p-value
= 0.0068).
The role of changes in appetite
232 (45.6%) of the 509 patients reported a general loss of
appetite (for details see Table 4), 30.6% of these 232
developed cachexia (types 1–3). We were especially inter-
ested in the patients with loss of appetite prior to initia-
tion of therapy; 14 (63.6%) of these 22 (4.3% of the 509)
patients developed cachexia. There seems to be a trend to
develop cancer cachexia more frequently at more
advanced tumour stages (Table 1). However, the small
numbers precluded a valid statistical analysis.
Among 249 patients who described an increased or an
unaltered appetite, only 32 (12.8%) developed cancer
cachexia. 18 of the total of 509 patients complained about
Table 2: Patients heterozygous for the MC4R Val103Ile polymorphism, grouped according to tumour type; presence or absence of 
cachexia is shown
Type of cancer Heterozygotes for 
the 103Ile-allele
cachectic I/II1,2 or related 
stages
III/IV1,2 or related 
stages
No data about 
stage
n female n male
Lymphoma 90 5 4 0 3 6
Colorectal 70 1 6 0 2 5
Leukaemia 20 * * * 0 2
Other 
gastrointestinal
10 0 1 0 0 1
Lung 10 1 0 0 0 1
Breast 20 2 0 0 2 0
Leukaemia-early 
stages
21 0 0 % * * * 1 1
Prostate 00 * * * 0 0
Others 1 (PNET5)0 * * * 0 1
Total 25 8% *** 81 7
1Lymphoma subgroups according to WHO (2001) and Ann Arbor classifications.
+The 24 patients with CLL (classification of Binet) and the 44 patients with multiple myeloma (classification of Durie and Salmon) were excluded.
2UICC classification was used for colorectal and other gastrointestinal tumors, breast and lung cancer.
3The different classifications for leucaemia and the leukaemia-early stages could not be used for these groups.
4Patients with myelodysplastic syndromes (MDS) or myeloproliferative syndromes (MPD).
5PNET: Primitive Neuroectodermal Tumour
*The classifications for these different tumour types could not be used for subgrouping.BMC Cancer 2008, 8:85 http://www.biomedcentral.com/1471-2407/8/85
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experiencing both phases of craving and revulsion.
Finally, 10 of all patients could not give any information
pertaining to appetite. Exploratively, we tested for an asso-
ciation between cancer cachexia status (types 1–3 vs. types
4,5) and changes of appetite in two groups (loss of appe-
tite vs. increase of appetite/no change with the former
group comprising loss of appetite in general, prior to ini-
tiation of therapy or during therapy and occurrence of
both food craving and revulsion; see Table 5a; Fisher's
exact test, two-sided, p = 9.2 × 10-6).
The role of changes in appetite in Ile103 carriers
Finally, we examined whether there might be an associa-
tion between changes of appetite defined as above in two
groups and the 103Ile allele of the Val103Ile polymor-
phism. 14 of the 25 heterozygous patients (56%, one of
them was cachectic) did not suffer from decreased appe-
tite. One patient could not give any information. The
remaining ten patients (40%, one of them was cachectic)
stated loss of appetite, three of them explained that the
decrease was due to the therapy, one experienced both
food craving and revulsion, two patients reported a loss of
appetite prior to initiation of therapy, none of them devel-
oped cachexia. Exploratively, both without and upon
exclusion of the two cases with preliminary leukaemic
stages we did not detect a significant association between
changes of appetite and the 103Ile allele of the Val103Ile
polymorphism (see Table 4; Fisher's exact test, two-sided
both p > 0.39).
Discussion
The Ile103 allele of the Val103Ile polymorphism of the
MC4R gene has repeatedly been reported in several stud-
ies with a large number of cases and controls to be nega-
tively associated with obesity and increased BMI [21-23].
In the light of the postulated role of the MC4R in develop-
ment of cachexia as determined in different rodent stud-
ies, we hypothesized that heterozygotes for the 103Ile
allele are more prone to develop cancer cachexia. Surpris-
ingly, our study did not provide any evidence for such an
association (p = 0.13). Exploratory post-hoc analyses
excluding patients with early leukaemic stages even
revealed that there might be a trend towards the opposite
effect (p < 0.05); heterozygotes for the 103Ile allele devel-
oped cancer cachexia less frequently in comparison to the
Table 4: Change of appetite and cachexia status (as defined in Methods) and MC4R 103Ile allele carrier status
Patients with Total
N1 = 499
[N = 479]
Cachexia
N = 105 (21.1)
[N = 100]
No cachexia
N = 394 (78.9)
[N = 379]
Heterozygotes for the 
103Ile- allele
N = 24 (4.8)
[N = 22]
Homozygotes for the 
Val103-allele
N = 475 (95.2)
[N = 457]
Loss of appetite: 232 (46.5)
[223]
71 (67.6)
[69]
161 (40.9)
[154]
9 (37.5)
[8]
223 (46.9)
[215]
General, not further specified 95 (19)
[91]
37 (35.2)
[36]
58 (14.7)
[55]
4 (16.7)
[3]
91 (19.1)
[88]
Prior to initiation of therapy 22 (4.4)
[21]
14 (13.3)
[14]
8 (2.1)
[7]
2 (8.3)
[2]
20 (4.2)
[19]
During therapy 115 (23.1)
[111]
20 (19.1)
[19]
95 (24.1)
[92]
3 (12.5)
[3]
112 (23.6)
[108]
Occurrence of both food 
craving and revulsion
18 (3.6)
[18]
2 (1.9)
[2]
16 (4)
[16]
1 (4.2)
[1]
17 (3.6)
[17]
Increase of appetite/no 
change
249 (49.9)
[238]
32 (30.5)
[29]
217 (55.1)
[209]
14 (58.3)
[13]
235 (49.5)
[225]
1N = 499 [479]: Of the 509 patients ten without information were excluded, because the patients did not give any information or could not 
remember their appetite.
Numbers in square brackets denote the number of patients without early leucaemic preliminary stages.
Numbers in parentheses denote the particular percentage.
Table 3: Heterozygotes for the MC4R 103Ile-allele and cachexia status (as defined in Methods)
Patients with Cachexia
N = 107 (21) [102]
No cachexia
N = 402 (79) [387]
Total
 N = 509 [489]
Heterozygotes for the 103Ile-allele 2 [0] 23 [23] 25 [23]
No Heterozygotes for the 103Ile-allele 105 [102] 379 [364] 484 [466]
Numbers in square brackets denote the number of patients without early leucaemic preliminary stages.
Numbers in parentheses denote the particular percentage.
Fisher's exact test, two sided, p-value = 0.13 [0.0068]BMC Cancer 2008, 8:85 http://www.biomedcentral.com/1471-2407/8/85
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rest of the study group. If this observation is not simply
due to the usual problems of post-hoc subgroup analyses
[36], one may speculate that there is a negative correlation
between the Val103Ile polymorphism and cancer
cachexia in patients with non-hematological/solid malig-
nant neoplasms. This hypothesis has to be tested in addi-
tional studies.
If there is indeed a 'protective effect' conferred by the
103Ile allele that prevents patients with cancer from
developing cachexia, it would be of interest to determine
the underlying mechanisms. It is assumed that the Ile103
allele itself (or another variant in tight linkage disequilib-
rium) leads to a more active MC4R in functional terms
[21]. Since endogenous agonist binding properties and
cell surface receptor expression levels are normal for this
Val103Ile polymorphism, it had been difficult to link the
Ile103 allele with a potential molecular effect. Recently, it
was however, observed that the 103Ile MC4R showed a
modest (2-fold) but statistically significant decrease in
antagonist hAGRP(87–132) potency, which is consistent
with a protective effect conferred by this variant [24]. The
effect of β-MSH, a potent agonist at the MC4R [25],
seemed, on the other hand, to be increased for the 103Ile-
allele [24]. Hence, both, the lower antagonist and the
increased agonist potencies are compatible with an ele-
vated MC4R function, which could explain the weight
reducing effect of the variant. However, these functional
findings [23-25], which are compatible with an elevated
MC4R function, cannot explain the possible protection
against the development of cachexia. There might be dif-
ferences in binding of these or other endogenous ligands
receptor-expression, in signal-transduction and/or physi-
ological conditions [21].
Other explanations include: (i) There might be cachexia
inducing factors that are produced by the tumour or
resulting from host-tumour-interactions that preferen-
tially react with the Ile103 variant. Deactivation or altered
binding properties might ensue. This mechanism might
lead to a reduced signalling of the MC4R expressing cells
and thus result in an inborn resistance to the development
of cancer cachexia. (ii) Alternatively, in the presence of
cancer certain factors/conditions might alter the receptor,
so that binding properties for an antagonist (e.g. AGRP)
might improve. (iii) Acute-phase-protein-levels are ele-
vated in patients developing cancer cachexia [37], possi-
bly the interaction between one or a combination of these
with the variant MC4R leads to the described effects.
To clarify if the risk of Ile103 carriers for development of
cancer cachexia and potentially other forms of cachexia
differs from wild type carriers, further studies in patients
with solid tumors, and in comparison to non-solid malig-
nant neoplasms are obviously warranted. Due to the car-
rier frequency in the range of 2–4% this evidently requires
large and appropriately characterized patient samples.
Not surprisingly, an exploratory sub-group analysis
revealed that changes of appetite (including loss of appe-
tite in general, prior to initiation of therapy or during ther-
apy and occurrence of both food craving and revulsion)
might be associated with cancer cachexia (p < 0.01). This
description is in line with previous studies [3,35]. Interest-
ingly, many patients could not concretize, some patients
could not give any information pertaining to appetite per-
taining to appetite; thus it was difficult to separate. We
were especially interested in the patients with loss of appe-
tite prior to initiation of therapy; 63.6% of these devel-
oped cachexia. However, loss of appetite does not seem to
be necessary for developing cachexia, as already described
in the past [4]. Finally, we also obtained no evidence for
an association of 103Ile carrier status and changes of
appetite (p > 0.39).
Conclusion
In sum, our data do not support the hypothesis of a higher
frequency of the 103Ile allele in patients developing can-
cer cachexia; contrariwise the frequency was descriptively
higher in patients not developing cachexia. Thus, the role
of the Val103Ile polymorphism of the MC4R  for the
development of cancer cachexia needs further clarifica-
tion. Nevertheless, our data provide investigators with a
basis to develop new hypotheses.
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